MSS
NVO

Mitchell Sinkler & Starr’s Novo Nordisk NVO Stock Holding History

Mitchell Sinkler & Starr’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,935
Closed -$218K – 142
2025
Q3 		$218K Buy
+3,935
New +$230K 0.1% 137
2024
Q4 		– Sell
-1,955
Closed -$233K – 195
2024
Q3 		$233K Hold
1,955
– – 0.06% 150
2024
Q2 		$254K Sell
1,955
-407
-17% -$53.9K 0.07% 137
2024
Q1 		$303K Sell
2,362
-498
-17% -$59.3K 0.08% 134
2023
Q4 		$296K Buy
+2,860
New +$283K 0.05% 160

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mitchell Sinkler & Starr's NVO Position: Q4 2025 in Review

Mitchell Sinkler & Starr sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,935 shares — an estimated $218K sold.

Mitchell Sinkler & Starr first reported a position in NVO in Q4 2023 and held it in 5 quarters. The position peaked at $303K in Q1 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Mitchell Sinkler & Starr reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Mitchell Sinkler & Starr sold 3,935 Novo Nordisk shares in Q4 2025, an estimated $218K.
  • Mitchell Sinkler & Starr first reported a position in Novo Nordisk in Q4 2023 and held it in 5 quarters.
  • Mitchell Sinkler & Starr's Novo Nordisk position peaked at $303K in Q1 2024.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Mitchell Sinkler & Starr's 13F filing for Q4 2025, filed 11 Feb 2026.